Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506117 | 0.86 | CTSK (0.47) | CTSKATMMAPTCTSSACE | |
| SCHEMBL1724454 | 0.85 | CTSK (0.48) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL14831003 | 0.85 | CTSK (0.48) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL1724453 | 0.85 | CTSK (0.48) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL12791268 | 0.78 | KMT2A (0.43) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL17041585 | 0.78 | KMT2A (0.43) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL17041589 | 0.78 | KMT2A (0.43) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL28299509 | 0.77 | CTSK (0.47) | CTSKATMMAPTCTSSACE | |
| SCHEMBL27951541 | 0.77 | KMT2A (0.45) | CA1CA2CA7CTSKKMT2A | |
| SCHEMBL13887000 | 0.77 | KMT2A (0.42) | CA1CA2CA7CTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1638557-A4 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2007-11-07 | — | — | EP | disclosed |
| EP-1824468-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006054298-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-05-26 | — | — | WO | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |
| EP-1638557-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000192-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | GSK3A, GSK3B, PYGB | CA1 4070/4885CA2 4242/4885CA7 4762/4885 |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GSKIP | CA1 3303/4885CA2 3292/4885CA7 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.